Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

. Based on the current expected level of receipts and expenditures, the company believes that its cash and cash equivalents are sufficient to support its activities into the fourth quarter of fiscal year 2009. The company will be eligible to receive a minimum milestone payment of $20 million from its U.S. partner, Strativa Pharmaceuticals, in the event that the planned NDA submission results in the company receiving marketing approval for ONCONASE.

Clinical/Regulatory Update

Alfacell has completed patient enrollment in a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Alfacell has requested a pre-NDA meeting with the Food and Drug Administration (FDA) to discuss the details of the planned NDA submission. The company continues to estimate that the final components of the rolling NDA will be submitted by the end of 2008, and the company plans to present the results of the Phase IIIb trial at an upcoming scientific conference in 2009.

The company has completed enrollment in its Phase I clinical trials for patients suffering from non-small cell lung cancer (NSCLC) and other solid tumors and is planning for a follow-on Phase II clinical trial in NSCLC patients that exhibit resistance to platinum based chemotherapy regimens. Initiation of patient enrollment in this tria
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CAMBRIDGE, MA (PRWEB) December 18, 2014 ... adults in the United States suffer from one or ... arthritis, asthma, or cancer. Medication can address some of ... to daily activities that many sufferers face. While implanted ... surgery and stimulate the whole nerve, which can induce ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3
... 19 Boston Scientific Corporation (NYSE: BSX ... Coronary Imaging Catheter, a product designed to improve the ... the iLab(R) Ultrasound Imaging System. IVUS technology enables ... coronary arteries. The Company said the iCross Catheter ...
... GmbH today announced,that it had defeated a request for insolvency, ... AGA Medical. , The request by ... that it had started the said request to recover damages.,However, ... a proceeding,regarding any damages has not yet been started. , ...
... Option to Extend Contract with Caliper -HOPKINTON, Mass., March ... CALP ), a leading provider of tools and services ... that the United States Environmental Protection Agency (EPA) presented ... Discovery Alliances and Services (CDAS) under the EPA,s ToxCast(TM) ...
Cached Biology Technology:Boston Scientific Launches New Coronary Imaging Catheter 2Boston Scientific Launches New Coronary Imaging Catheter 3Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical 2EPA Presents Initial Results from Caliper Life Sciences' ToxCast Screening Effort 2EPA Presents Initial Results from Caliper Life Sciences' ToxCast Screening Effort 3EPA Presents Initial Results from Caliper Life Sciences' ToxCast Screening Effort 4
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... will conduct a series of scientific studies aimed at protecting and ... Estuary, Jobos Bay, La Parguera and other marine areas around Puerto ... it docks in San Juan on Feb. 12 and in Mayaguez ... to the U.S. Virgin Islands, where its crew will study coral ...
... New research has found that modern lifestyle habits may play ... tooth decay. A review of the scientific evidence ... fluoride toothpaste, good oral hygiene and health education, may override ... is published online in a Supplement to the journal ...
... (SIR) will present the latest research on treatments ... herniated disks; peripheral arterial disease (PAD) and related ... Annual Scientific Meeting March 7-12� at the San ... Highlights of embargoed key interventional radiology studies ...
Cached Biology News:EPA to study Puerto Rico waters and marine habitat 2Society of Interventional Radiology hosts 34th annual scientific meeting 2Society of Interventional Radiology hosts 34th annual scientific meeting 3Society of Interventional Radiology hosts 34th annual scientific meeting 4